FR18C1043I2 - Therapie antivirale - Google Patents

Therapie antivirale

Info

Publication number
FR18C1043I2
FR18C1043I2 FR18C1043C FR18C1043C FR18C1043I2 FR 18C1043 I2 FR18C1043 I2 FR 18C1043I2 FR 18C1043 C FR18C1043 C FR 18C1043C FR 18C1043 C FR18C1043 C FR 18C1043C FR 18C1043 I2 FR18C1043 I2 FR 18C1043I2
Authority
FR
France
Prior art keywords
antiviral therapy
antiviral
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1043C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare Co
Original Assignee
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1043(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ViiV Healthcare Co filed Critical ViiV Healthcare Co
Publication of FR18C1043I1 publication Critical patent/FR18C1043I1/fr
Application granted granted Critical
Publication of FR18C1043I2 publication Critical patent/FR18C1043I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR18C1043C 2010-01-27 2018-10-15 Therapie antivirale Active FR18C1043I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
EP11737484.3A EP2531027B1 (fr) 2010-01-27 2011-01-24 Combinaison thérapeutique comprenant du dolutégravir, de l'abacavir et de la lamivudine

Publications (2)

Publication Number Publication Date
FR18C1043I1 FR18C1043I1 (fr) 2018-11-30
FR18C1043I2 true FR18C1043I2 (fr) 2019-10-11

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1043C Active FR18C1043I2 (fr) 2010-01-27 2018-10-15 Therapie antivirale

Country Status (45)

Country Link
US (12) US20120295898A1 (fr)
EP (6) EP3351249A1 (fr)
JP (8) JP2013518107A (fr)
KR (4) KR101964923B1 (fr)
CN (2) CN105311033B (fr)
AP (1) AP3551A (fr)
AU (1) AU2011209788C1 (fr)
BR (1) BR112012018670A2 (fr)
CA (4) CA2787691C (fr)
CL (1) CL2012002080A1 (fr)
CO (1) CO6602152A2 (fr)
CR (1) CR20120423A (fr)
CY (4) CY1116509T1 (fr)
DK (4) DK2932970T3 (fr)
DO (2) DOP2012000205A (fr)
EA (4) EA032868B1 (fr)
EC (1) ECSP12012106A (fr)
ES (4) ES2670811T3 (fr)
FI (2) FI3494972T3 (fr)
FR (1) FR18C1043I2 (fr)
HK (3) HK1209629A1 (fr)
HR (4) HRP20240168T1 (fr)
HU (4) HUE037812T2 (fr)
IL (5) IL221007A (fr)
LT (4) LT3494972T (fr)
LU (1) LUC00090I2 (fr)
MA (1) MA34002B1 (fr)
ME (2) ME03058B (fr)
MX (4) MX2012008774A (fr)
MY (1) MY188334A (fr)
NO (2) NO2932970T3 (fr)
NZ (4) NZ627824A (fr)
PE (2) PE20160180A1 (fr)
PH (2) PH12016500195A1 (fr)
PL (4) PL3127542T3 (fr)
PT (4) PT3127542T (fr)
RS (4) RS65183B1 (fr)
SG (3) SG10201509476RA (fr)
SI (4) SI2531027T1 (fr)
SM (1) SMT201500177B (fr)
TN (1) TN2012000376A1 (fr)
TR (1) TR201807704T4 (fr)
UA (1) UA105556C2 (fr)
WO (1) WO2011094150A1 (fr)
ZA (1) ZA201205586B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2670811T3 (es) 2010-01-27 2018-06-01 Viiv Healthcare Company Terapia antivírica
MX364901B (es) 2012-10-23 2019-05-10 Cipla Ltd Composicion farmaceutica antirretroviral.
MY164352A (en) 2012-12-21 2017-12-15 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2956123A1 (fr) * 2013-02-18 2015-12-23 ratiopharm GmbH Forme galénique pharmaceutique solide de dolutegravir
EP2767272A1 (fr) * 2013-02-18 2014-08-20 Ratiopharm GmbH Forme posologique pharmaceutique solide de dolutegravir
NO2865735T3 (fr) 2013-07-12 2018-07-21
PL3252058T3 (pl) 2013-07-12 2021-07-19 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
SG11201602217XA (en) 2013-09-27 2016-04-28 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015140569A1 (fr) 2014-03-20 2015-09-24 Cipla Limited Composition pharmaceutique
WO2015187998A2 (fr) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Utilisation d'un inhibiteur des antagonistes de la protéine d'apoptose (iap) dans une thérapie contre le vih
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP6603306B2 (ja) 2014-07-29 2019-11-06 レツク・フアーマシユーテイカルズ・デー・デー ドルテグラビルナトリウムの新規な水和物
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN107531727B (zh) 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
WO2017029225A1 (fr) * 2015-08-14 2017-02-23 Sandoz Ag Composition pharmaceutique solide d'abacavir, de lamivudine et d'efavirenz
WO2017205585A1 (fr) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinaisons, utilisations et traitements correspondants
WO2018028841A1 (fr) * 2016-08-12 2018-02-15 Sandoz Ag Composé pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz.
WO2018042332A1 (fr) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US11564921B2 (en) 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
JP2020536931A (ja) * 2017-10-13 2020-12-17 ヴィーブ ヘルスケア カンパニー 二層医薬錠剤製剤
MX2021011394A (es) 2019-03-22 2021-10-13 Gilead Sciences Inc Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
WO2021173522A1 (fr) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Composés tétracycliques pour le traitement d'une infection par le vih
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
WO2023164293A1 (fr) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Méthodes d'infections virales

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
CN1228026A (zh) * 1996-06-25 1999-09-08 葛兰素集团有限公司 用于治疗hiv感染的含有vx478、叠氮胸苷、ftc和/或3tc的复方制剂
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
CA2398640C (fr) 2000-01-31 2011-06-14 Cook Biotech Incorporated Valvules sur stents et leur utilisation
PL217629B1 (pl) 2001-04-10 2014-08-29 Pfizer Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW200403061A (en) 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
MXPA04012754A (es) * 2002-06-27 2005-03-23 Medivir Ab Interaccion sinergica de abacavir y alovudina.
US20060246130A1 (en) * 2003-01-14 2006-11-02 Dahl Terrence C Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
RU2006128848A (ru) * 2004-02-11 2008-03-20 СмитКлайн Бичем Корпорейшн (US) Ингибиторы вич-интегразы
CA2562713A1 (fr) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Analogues de phosphonate de composes inhibiteurs de l'integrase du vih
WO2005112930A1 (fr) * 2004-05-21 2005-12-01 Japan Tobacco Inc. Associations comprenant un dérivé de 4-isoquinolone et des agents anti-vih
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
ES2358269T3 (es) 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
SG155939A1 (en) 2004-09-17 2009-10-29 Idenix Pharmaceuticals Inc Phosphoindoles as hiv inhibitors
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
SI3045206T1 (en) * 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
CA2847871C (fr) * 2005-12-30 2016-07-26 Gilead Sciences, Inc. Procedes pour l'amelioration de la pharmacocinetique d'inhibiteurs de l'integrase vih
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
SI1981506T1 (sl) * 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
WO2008011117A2 (fr) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Inhibiteurs de protéase antiviraux
KR20090077813A (ko) 2006-09-29 2009-07-15 아이데닉스 파마슈티칼스, 인코포레이티드 Ｈｉｖ 억제제로서의 거울상이성질체적으로 순수한 포스포인돌
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
AU2008218186C1 (en) 2007-02-23 2014-07-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2533863T3 (es) 2007-06-29 2015-04-15 Korea Research Institute Of Chemical Technology Inhibidores novedosos de la transcriptasa inversa de VIH
WO2009005693A1 (fr) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Nouveaux inhibiteurs de la transcriptase inverse de vih
ES2438275T3 (es) 2007-07-06 2014-01-16 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
WO2009007441A2 (fr) 2007-07-12 2009-01-15 Tibotec Pharmaceuticals Ltd. Forme cristalline de 4-[[4-[[4-(2-cyanoéthényl)-2,6-diméthylphényl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2009058923A1 (fr) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Antagonistes de ccr5 en tant qu'agents thérapeutiques
EP2217573A4 (fr) 2007-11-01 2011-08-31 Uab Research Foundation Traitement et prévention d'infections virales
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
JP2011508748A (ja) * 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のルパン誘導体
CN101977924A (zh) 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
ES2555209T3 (es) 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
WO2009100532A1 (fr) 2008-02-14 2009-08-20 Virochem Pharma Inc. Nouveaux dérivés de 17ss-lupane
WO2009148600A2 (fr) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Composés à base de lysine deutérée
EP2320908B9 (fr) * 2008-07-25 2014-06-18 VIIV Healthcare Company Prodrugs de dolutegravir
CN102245182B (zh) * 2008-12-11 2014-07-23 盐野义制药株式会社 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成
CN106986823A (zh) * 2008-12-11 2017-07-28 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
ES2670811T3 (es) 2010-01-27 2018-06-01 Viiv Healthcare Company Terapia antivírica
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (fr) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation

Also Published As

Publication number Publication date
CA2787691C (fr) 2018-07-17
FIC20240016I1 (fi) 2024-05-31
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
US20170119777A1 (en) 2017-05-04
EP3351249A1 (fr) 2018-07-25
PT3494972T (pt) 2024-02-12
PH12018502489A1 (en) 2020-06-15
EP3127542B1 (fr) 2018-08-22
CY1116509T1 (el) 2017-03-15
DK2531027T3 (en) 2015-07-20
NO2018036I1 (no) 2018-10-15
SI3127542T1 (sl) 2018-11-30
CL2012002080A1 (es) 2012-11-30
EP2531027A1 (fr) 2012-12-12
IL267658A (en) 2019-08-29
SMT201500177B (it) 2015-09-07
JP2013518107A (ja) 2013-05-20
SI2531027T1 (sl) 2015-08-31
BR112012018670A2 (pt) 2018-02-06
DOP2012000205A (es) 2012-10-15
MX2012008774A (es) 2012-08-17
PH12016500195B1 (en) 2016-12-05
ES2688925T3 (es) 2018-11-07
IL245182A0 (en) 2016-06-30
EA032868B1 (ru) 2019-07-31
EP3494972B1 (fr) 2023-12-13
EP3494972A1 (fr) 2019-06-12
CA2967453C (fr) 2018-07-17
JP2018127473A (ja) 2018-08-16
PT2531027E (pt) 2015-09-16
LT2932970T (lt) 2018-06-25
CO6602152A2 (es) 2013-01-18
KR101883750B1 (ko) 2018-07-31
MX356891B (es) 2018-06-19
IL281959B (en) 2021-12-01
EA201690872A2 (ru) 2016-08-31
US20210401850A1 (en) 2021-12-30
HRP20181531T1 (hr) 2018-11-16
US20150238496A1 (en) 2015-08-27
EA202190473A2 (ru) 2021-06-30
JP6268386B2 (ja) 2018-01-31
IL221007A (en) 2016-06-30
ECSP12012106A (es) 2013-05-31
IL257267A (en) 2018-03-29
MA34002B1 (fr) 2013-02-01
KR101964923B1 (ko) 2019-04-02
LTC2932970I2 (lt) 2022-04-25
DK2932970T3 (en) 2018-05-28
PL3494972T3 (pl) 2024-05-27
PT3127542T (pt) 2018-11-26
LT3494972T (lt) 2024-03-12
US20160199379A1 (en) 2016-07-14
CA3003988A1 (fr) 2011-08-04
JP2017008087A (ja) 2017-01-12
SG10201707183TA (en) 2017-10-30
US20170216284A1 (en) 2017-08-03
US20200230147A1 (en) 2020-07-23
DK3494972T3 (da) 2024-01-29
JP2023085431A (ja) 2023-06-20
NZ601319A (en) 2014-08-29
EP3127542A1 (fr) 2017-02-08
PL2932970T3 (pl) 2018-08-31
JP2016145204A (ja) 2016-08-12
EA202190473A3 (ru) 2021-12-31
NZ627824A (en) 2016-02-26
KR20160111536A (ko) 2016-09-26
CA2787691A1 (fr) 2011-08-04
ES2543066T3 (es) 2015-08-14
US20180098992A1 (en) 2018-04-12
PL2531027T3 (pl) 2016-01-29
AU2011209788C1 (en) 2014-08-28
CA3060290A1 (fr) 2011-08-04
TN2012000376A1 (en) 2014-01-30
KR101830715B1 (ko) 2018-04-04
FR18C1043I1 (fr) 2018-11-30
PT2932970T (pt) 2018-06-08
US11234985B2 (en) 2022-02-01
DOP2021000147A (es) 2022-01-16
HK1209629A1 (en) 2016-04-08
JP2022071126A (ja) 2022-05-13
MY188334A (en) 2021-11-30
AU2011209788B2 (en) 2014-02-06
MX367937B (es) 2019-09-12
EP2531027A4 (fr) 2013-07-03
EA037601B1 (ru) 2021-04-20
AU2011209788A1 (en) 2012-08-16
PL3127542T3 (pl) 2019-03-29
NZ627826A (en) 2016-01-29
KR20180078358A (ko) 2018-07-09
ES2670811T3 (es) 2018-06-01
EP2932970B1 (fr) 2018-03-21
CN102791129B (zh) 2015-09-30
ME02182B (me) 2015-10-20
DK3127542T3 (en) 2018-11-12
IL221007A0 (en) 2012-09-24
HK1250335A1 (zh) 2018-12-14
IL257267B (en) 2019-08-29
AP3551A (en) 2016-01-18
JP2019167371A (ja) 2019-10-03
IL267658B (en) 2021-04-29
WO2011094150A1 (fr) 2011-08-04
JP2021091705A (ja) 2021-06-17
RS57728B1 (sr) 2018-12-31
EA025176B1 (ru) 2016-11-30
TR201807704T4 (tr) 2018-06-21
CA3060290C (fr) 2022-07-12
CN102791129A (zh) 2012-11-21
US20170079982A1 (en) 2017-03-23
EP4316599A3 (fr) 2024-04-10
US20170281636A1 (en) 2017-10-05
NO2932970T3 (fr) 2018-08-18
US10426780B2 (en) 2019-10-01
CN105311033B (zh) 2019-05-07
ME03058B (fr) 2019-01-20
HUS1800042I1 (hu) 2018-11-28
CY1120457T1 (el) 2019-07-10
EA201690872A3 (ru) 2016-12-30
IL245182B (en) 2018-04-30
KR20120128640A (ko) 2012-11-27
HUE026849T2 (en) 2016-08-29
PH12016500195A1 (en) 2016-12-05
SI2932970T1 (en) 2018-07-31
CY2018029I1 (el) 2019-07-10
CA2967453A1 (fr) 2011-08-04
NZ627827A (en) 2016-02-26
ES2969969T3 (es) 2024-05-23
EP2531027B1 (fr) 2015-05-06
CR20120423A (es) 2012-11-22
RS54123B1 (en) 2015-12-31
CY1121040T1 (el) 2019-12-11
HRP20150770T1 (hr) 2015-08-28
EA201892277A1 (ru) 2019-03-29
US20120295898A1 (en) 2012-11-22
CN105311033A (zh) 2016-02-10
AP2012006445A0 (en) 2012-08-31
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
EP4316599A2 (fr) 2024-02-07
SI3494972T1 (sl) 2024-03-29
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
EP2932970A1 (fr) 2015-10-21
PE20121524A1 (es) 2012-12-03
US20160339033A1 (en) 2016-11-24
CA3003988C (fr) 2020-01-07
FI3494972T3 (fi) 2024-03-01
HRP20180855T1 (hr) 2018-06-29
LUC00090I2 (fr) 2019-01-08
HUE040554T2 (hu) 2019-03-28
EA201290583A1 (ru) 2013-04-30
MX367938B (es) 2019-09-12
LT3127542T (lt) 2018-11-26
IL281959A (en) 2021-05-31
SG10201509476RA (en) 2015-12-30
HUE037812T2 (hu) 2018-09-28
US20180200254A1 (en) 2018-07-19
KR20170078868A (ko) 2017-07-07
LTPA2018013I1 (lt) 2018-11-12
HK1179522A1 (en) 2013-10-04
RS65183B1 (sr) 2024-03-29
UA105556C2 (uk) 2014-05-26

Similar Documents

Publication Publication Date Title
FR18C1043I2 (fr) Therapie antivirale
SMT201600400B (it) Inalatore
BR112013013026A2 (pt) inalador
DK2760886T3 (da) Immunocytokin-kombinationsterapi
BR112013033974A2 (pt) terapia de combinação
FI20115876A0 (fi) Yhdistelmähoito
BR112012027133A2 (pt) inalador
FI20115640A0 (fi) Yhdistelmähoito
ES1075603Y (es) Objeto terapeutico
FR2964560B1 (fr) Stimulateur respiratoire
FIU20100462U0 (fi) Saunasumu
DK2663304T3 (da) Kombinationsterapi
DOS2011000168S (es) Inhalador
ES1075602Y (es) Almohadilla terapeutica
FI20100106A0 (fi) Kaaosprosessori
UA20603S (uk) Манекен - торс жіночий
UA20314S (uk) Манекен - торс жіночий
UA20315S (uk) Манекен - торс жіночий
UA20316S (uk) Манекен - торс чоловічий
DK2380545T3 (da) Terapi-indretning
ITNU20100010U1 (it) Massaggiatore infradito